Last reviewed · How we verify
NCT03682991: RASTA AF
Reversal of Atrial Substrate to Prevent Atrial
NA trial testing Aggressive Risk Factor Control in Atrial Fibrillation in 509 participants. Participants enrolled and being followed up; not accepting new ones.
15 September 2027
Quick facts
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 509 |
| Start date | 1 July 2019 |
| Primary completion | 15 September 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 17 locations across Canada |
Drugs / interventions tested
- Aggressive Risk Factor Control
- Standard of Care
Conditions studied
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
Sponsor
Nova Scotia Health Authority — full company profile →
Who can join
18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A multi-center, randomized trial to examine the effect of aggressive risk factor control and arrhythmia trigger-based intervention on recurrence of atrial fibrillation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03682991
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aggressive Risk Factor Control
Trials testing the same drug.
- NCT03186976 — Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study · NA · completed
Other recruiting trials for Atrial Fibrillation
Currently open trials in the same condition.
- NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
- NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
- NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
- NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
Other Nova Scotia Health Authority trials
Trials by the same sponsor.
- NCT03716999 — Starlight Therapy in Palliative Care · not yet recruiting
- NCT06987409 — Continuous Erector Spinae Block for Analgesia Following Lumbar Decompression · NA · not yet recruiting
- NCT06575621 — Knee-hip Surgery Wait-list Support Program · NA · not yet recruiting
- NCT07143162 — YOGA-FIT: Protocol for a Crossover Trial Investigating the Feasibility and Impact of Yoga for People With Stroke · NA · not yet recruiting
- NCT07239999 — Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03682991 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Scotia Health Authority
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03682991.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing